Clinical Scorecard: Evaluation of Treatment Response to Immune Checkpoint Inhibitors: A Comparative Analysis of iRECIST and RECIST 1.1 in Patients with Melanoma and Non-Small Cell Lung Cancer

At a Glance

Key Highlights

• Immune checkpoint inhibitors (ICI) improve overall and progression-free survival in melanoma and NSCLC.
• Pseudoprogression is an atypical response pattern under ICI, potentially misclassified as progressive disease by RECIST 1.1.
• iRECIST was developed to better capture atypical responses and standardize assessment during ICI therapy.

Guideline-Based Recommendations

Diagnosis

• Use histopathological confirmation for melanoma or NSCLC diagnosis before ICI therapy.
• Perform baseline contrast-enhanced CT of chest and abdomen within 12 weeks prior to ICI initiation.

Management

• Treat patients with CTLA-4 inhibitor ipilimumab, PD-1 inhibitors nivolumab or pembrolizumab, or combination therapy.
• Avoid concurrent chemotherapy or radiation during the observed ICI treatment period.

Monitoring & Follow-up

• Conduct at least two follow-up contrast-enhanced CT scans of chest and abdomen during or shortly after ICI therapy.
• Evaluate treatment response using both RECIST 1.1 and iRECIST criteria to identify atypical response patterns.
• Confirm progressive disease under iRECIST (iCPD) before treatment discontinuation to avoid premature cessation.

Risks

• Potential misclassification of pseudoprogression as progressive disease by RECIST 1.1 may lead to premature treatment discontinuation.
• Ambiguity in immune-related response criteria (irRECIST) can cause inconsistent PD confirmation across studies.

Patient & Prescribing Data

Patients with melanoma or NSCLC receiving immune checkpoint inhibitors without concurrent chemotherapy or radiation

ICI therapy shows improved survival; response evaluation requires criteria sensitive to atypical patterns like pseudoprogression to optimize treatment continuation decisions.

Clinical Best Practices

• Incorporate iRECIST alongside RECIST 1.1 for comprehensive assessment of ICI treatment response.
• Use experienced radiologists and consensus review for ambiguous imaging evaluations.
• Maintain standardized imaging protocols with contrast-enhanced CT scans for consistent response monitoring.
• Recognize and account for atypical response patterns such as pseudoprogression to prevent premature therapy discontinuation.

References

• RECIST 1.1 Guidelines
• iRECIST Guidelines
• Immune-related response criteria
• Pseudoprogression in Immune Checkpoint Therapy